MedTrace Logo

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

NCT00736528 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-02-25

No results posted yet for this study

Summary

To describe the safety, tolerability and pharmacokinetics of PF-04447943 after administration of multiple, ascending, oral doses to healthy elderly subjects.

Conditions

  • Healthy
  • Elderly

Interventions

DRUG

PF-04447943

05 mg BID for 14 days

DRUG

PF-04447943

15 mg BID for 14 days

DRUG

PF-04447943

45mg BID for 14 days

DRUG

Placebo

Placebo for 14 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736528 on ClinicalTrials.gov